Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACM Research Inc (ACMR) vs DexCom, Inc. (DXCM) Price & Performance

ACM Research IncTrade
DexCom, Inc.Trade

Price performance (Past 24H)

Key statistics

ACM Research Inc vs DexCom, Inc. — how do they compare? ACM Research Inc trades at $82.02 (market cap $5.57B), while DexCom, Inc. trades at $90.79 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 6.1× ACM Research Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, ACM Research Inc nearer its low. Which is the better fit depends on your goals.

ACMRDXCM
Market Cap
$5.57B$33.79B
Sector
TechnologyHealth
52-Week High
$126.89$89.53
52-Week Low
$24.93$54.84
Enterprise Value
$4.48B$33.24B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACM Research Inc

ACMR trades at $82.42, up 3.79% today, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings of $0.61 per share beat estimates, and revenue guidance was raised following strong order growth. The company shows robust profitability with a 14.48% net income margin and 10.56% ROE, though valuation ratios like a P/E of 37.7 appear elevated. Analyst sentiment is strongly bullish with an 80% buy rating and a $127.50 consensus price target.

The outlook is positive given earnings beats and raised guidance, but high valuation and cash flow challenges from negative operating cash flow pose risks. Upside potential exists if growth continues, yet investors face volatility from market conditions and execution risks in the competitive semiconductor equipment sector.

DexCom, Inc.

DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.

The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.

Returns comparison

Trailing returns across standard periods

About ACM Research Inc

ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.

Read more on ACMR

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM